Autism Spectrum Disorder
Neurodevelopmental condition characterized by differences in social communication and restricted/repetitive behaviors. Cannabis has insufficient high-quality evidence for treating core autism symptoms; limited evidence exists for managing severe behavioral symptoms in specific subgroups.
- 26 states
- QUALIFYING IN
- Insufficient
- EVIDENCE
- F84.0
- ICD-10
- 1
- ARTICLES
Reviewed by Laura H. Meyer
Qualifying states
What it is
Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by differences in social communication, restricted or repetitive behaviors and interests, and sensory processing. Symptom severity ranges widely, from individuals requiring substantial daily support to those who live independently with minimal accommodation.
There is no medical treatment for the core neurodevelopmental features of ASD. Behavioral interventions and applied behavior analysis remain standard. Pharmacotherapy targets co-occurring symptoms (anxiety, irritability, seizures, sleep disturbance).
Cannabis and cannabis-derived therapies
Evidence for cannabis or cannabinoids in autism is insufficient for core symptom treatment. Small open-label studies of cannabidiol (CBD) and CBD-rich formulations have reported improvements in irritability, hyperactivity, sleep, and self-injurious behavior in subgroups of pediatric and young-adult patients with severe ASD. Sample sizes are small and randomized controlled trial data are limited.
ASD is a qualifying condition under several state medical cannabis programs. Notably Texas, Pennsylvania, Minnesota, and Georgia. Many of these programs explicitly restrict pediatric access to CBD-dominant, low-THC formulations.
Important pediatric warning: THC has documented adverse effects on the developing adolescent brain, including elevated risks for psychosis spectrum disorders, cognitive impairment, and dependence when initiated before age 25. Parents, legal guardians, and clinicians considering cannabis for a pediatric or adolescent patient with ASD should weigh these risks carefully, favor CBD-only formulations where possible, and proceed only in close coordination with the patient's developmental pediatrician, psychiatrist, or designated specialist.
Frequently asked questions
Does cannabis treat the core features of autism?
No. There is no high-quality evidence that cannabis or cannabinoids treat the core neurodevelopmental features of autism spectrum disorder. Behavioral interventions and applied behavior analysis remain the standard of care. Cannabis use in ASD has been studied mainly for co-occurring symptoms such as agitation, irritability, and sleep disturbance.
Is any cannabis-derived product FDA-approved for autism?
No. No cannabis-derived medication is FDA-approved for autism spectrum disorder. Epidiolex (cannabidiol) is FDA-approved for specific epilepsy syndromes (including tuberous sclerosis complex, which has higher autism prevalence) but the approval is for seizure control, not autism symptoms.
What does pediatric cannabis use require parents and caregivers to consider?
Pediatric cannabis use carries higher risk than adult use: developing brains are more sensitive to THC, and chronic exposure is associated with cognitive and mental-health harms. State programs that allow pediatric ASD enrollment typically require designated caregivers, physician certification, and CBD-dominant or low-THC formulations. AAP guidance is that cannabis is not recommended for pediatric use outside the FDA-approved Epidiolex indications.
Which states include autism as a qualifying condition?
A growing minority of state medical-cannabis programs enumerate severe or intractable autism as a qualifying condition, sometimes restricted to patients with self-injurious or aggressive behaviors. Examples include Iowa, Pennsylvania, Minnesota, and Oklahoma. Inclusion is typically narrower than for other qualifying conditions and pediatric safeguards are common.
Sources
- CDC: Autism Spectrum Disorderaccessed May 15, 2026
- NIH NCCIH: Cannabis (Marijuana) and Cannabinoidsaccessed May 15, 2026